Although patients with CHIP did not have an increased risk of cardiovascular disease (CVD), patients with only DNMT3A mutations did have an increased risk of cardiovascular events (Figure 1); this risk was independent (HR 6.637, 95% CI 1.443–30.533, p = 0.015) of those with CHIP, coronary calcifications, stage 5 CKD, and phosphorus. Here, DNMT3A is linked to cardiovascular disorder.